NAUT · 10-Q · 2026Q1

Nautilus Biotechnology, Inc.

Filed 2026-04-28 · Industrials

Ranked Events

• Liquidity and Cash PositionImportance 60 · Surprise 24
  As of March 31, 2026, Nautilus reported cash, cash equivalents and investments of $143.4 million and states it believes its existing cash resources will enable funding of planned operating expenses and capital…
• Guidance / OutlookImportance 59 · Surprise 60
  Nautilus expects expenses and capital requirements to increase substantially as it advances product development, establishes service laboratory operations, builds sales/marketing/distribution capabilities, and invests…
• Equity Offering ProgramsImportance 56 · Surprise 24
  Nautilus has an at-the-market Sales Agreement with TD Cowen, entered in February 2024, to offer and sell up to $125.0 million of common stock from time to time. TD Cowen may receive up to 3.0% of gross proceeds as…
• Operating Expense TrendsImportance 54 · Surprise 40
  Total operating expenses decreased 14% year-over-year, driven by declines in both research and development and selling, general and administrative expenses. R&D expense was $9.7 million for the three months ended March…
• Investing Activities and SecuritiesImportance 53 · Surprise 48
  Net cash provided by investing activities was $14.2 million in Q1 2026, driven by $25.8 million of proceeds from maturities of securities partially offset by $11.1 million of purchases of securities and $0.5 million of…
• Regulatory / Compliance CostsImportance 52 · Surprise 42
  Nautilus expects selling, general and administrative expenses to increase substantially over the next several years as it hires personnel to support R&D and planned commercial growth and as it operates as a public…
• Product Launch and TransitionImportance 48 · Surprise 60
  Nautilus launched an Iterative Mapping Early Access Program in January 2026 beginning with target-specific service offerings for the microtubule-associated protein tau ("Tau") and expects to extend the program to…
• Research and Development ExpenseImportance 48 · Surprise 40
  Research and development expenses were $9.7 million for the three months ended March 31, 2026, down from $11.5 million in the three months ended March 31, 2025, a decrease of $1.8 million, or 16%. The decrease included…
• Operating Cash Flow TrendsImportance 43 · Surprise 32
  Net cash used in operating activities was $13.1 million for the three months ended March 31, 2026, compared with $13.9 million in the year‑ago quarter. Q1 2026 operating cash use resulted from the net loss of $14.7…
• Selling, General and Administrative ExpenseImportance 42 · Surprise 40
  Selling, general and administrative (SG&A) expenses were $6.4 million for the three months ended March 31, 2026, versus $7.3 million in the comparable 2025 quarter, a decrease of $0.9 million, or 12%. The primary…
• Quarterly Results SnapshotImportance 41 · Surprise 22
  Nautilus reported a net loss of $14.7 million for the three months ended March 31, 2026. The net loss improved by $1.9 million, or 12%, versus a $16.6 million loss in the same period of 2025. The company stated it has…
• Interest Rate and Refinancing ExposureImportance 40 · Surprise 56
  Other income declined as interest income fell to $1.442 million for the three months ended March 31, 2026 from $2.231 million in the prior-year period, a 35% decrease ($0.789 million) attributed to a lower…
• Interest Income and Investment YieldImportance 40 · Surprise 56
  Interest income fell to $1.4 million in Q1 2026 from $2.2 million in Q1 2025, a decline of $0.8 million, or 35%. Management attributes the decrease to a lower balance of cash, cash equivalents and investments and to…
• Manufacturing and CapacityImportance 39 · Surprise 48
  To commercialize the Nautilus Voyager platform in volume, the company will need to establish internal manufacturing capacity, contract with manufacturing partners, or both, due to the platform’s complex manufacturing…
• Headcount / RestructuringImportance 34 · Surprise 42
  Nautilus implemented a workforce reduction in the first quarter of 2025. Management attributes part of the year-over-year decreases in both R&D and SG&A expenses to cost savings from that reduction in force. The filing…
• Customer Dynamics and Early CollaborationsImportance 31 · Surprise 42
  Nautilus is engaging early with leading biopharmaceutical companies, academic institutions and research organizations through research collaborations and Early Access to evaluate pre-commercial versions of the Voyager…
• Distribution Channels and Sales BuildoutImportance 31 · Surprise 42
  Nautilus plans to commercialize the Voyager platform through a direct sales channel in the United States and through both direct and distributor channels outside the U.S. The company is in the early stages of building…
• Market Demand TrendsImportance 31 · Surprise 42
  Nautilus expects demand to be developed through phased commercialization beginning with research collaborations and an Early Access Program targeting biopharmaceutical companies, academic institutions, and research…
• Supply Chain ConstraintsImportance 29 · Surprise 24
  Nautilus reports having experienced supply disruptions in the past, including closures at certain chip manufacturers that caused extended lead times for chips and reduced availability of certain reagents. The company…
• Macroeconomic Factors ImpactImportance 13 · Surprise 6
  Nautilus states that its business may be affected by a range of global and national events, explicitly citing extreme weather, economic uncertainty, increased tariffs, inflation, changing interest rates, potential…